At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
FX006 32 mgdrug
Likely dose
FX006 32 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Open-label Study to Evaluate a Procedure for Intra-articular (IA) Injection of FX006 in Patients With Osteoarthritis (OA) of the Hip
In Brief
A Phase 2 clinical trial evaluating FX006 32 mg for Osteoarthritis, Hip. Completed, enrolled 16 participants across 5 sites.
Detailed Summary
This is a multi-center, single-arm, open-label study of FX006 in patients with hip OA. A maximum number of approximately 30 patients may be enrolled in this protocol. All enrolled patients will receive a single intra-articular (IA) injection of FX006.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Hip
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJul 2019
First PostedAug 2019
Primary CompletionOct 2019
Study CompletionDec 2019
TodayJul 2026
First PostedAug 22, 2019
Enrollment StartJul 30, 2019
Primary CompletionOct 11, 2019
Study CompletionDec 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.9 years ago
Interventions
FX006 32 mgdrug
Extended-release 32 mg FX006 IA injection